Evommune (EVMN) Change in Accured Expenses (2024 - 2026)

Evommune (EVMN) has 3 years of Change in Accured Expenses data on file, last reported at -$4.8 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$4.8 million, down 128.97% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.8 million (changed N/A YoY), and the FY2025 annual result was $2.8 million, up 4.22% from the prior year.
• Change in Accured Expenses slipped to -$4.8 million in Q1 2026 per EVMN's latest filing, from $4.3 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $4.3 million in Q4 2025 and troughed at -$4.8 million in Q1 2026.
• A 3-year average of -$689500.0 and a median of -$1.1 million in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses jumped 3169.29% in 2025, then tumbled 128.97% in 2026.
• A 3-year view of Change in Accured Expenses shows it stood at -$140000.0 in 2024, then jumped by 3169.29% to $4.3 million in 2025, then sank by 212.01% to -$4.8 million in 2026.
• Business Quant data shows EVMN's Change in Accured Expenses at -$4.8 million in Q1 2026, $4.3 million in Q4 2025, and -$2.1 million in Q1 2025.